An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans

Background: TV-46000 (Uzedy, Teva), a long-acting subcutaneous antipsychotic, is an injectable formulation of risperidone and is approved by the FDA for the treatment of schizophrenia in adults. Its innovative copolymer-based drug delivery depot technology (licensed from MedinCell, Jacou, France) al...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lilach Steiner, David Bibi, Avia Merenlender Wagner, Pavel Farkas, Safra Rudnick-Glick, Pippa Loupe, Hussein Hallak
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-01-01
Edice:	Pharmaceutics
Témata:	risperidone TV-46000 schizophrenia long-acting injectable antipsychotic drug delivery depot technology
On-line přístup:	https://www.mdpi.com/1999-4923/17/2/150
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!